{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:53:31Z","timestamp":1773957211408,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004962","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000}}],"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH123267"],"award-info":[{"award-number":["R01 MH123267"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R00 MH118134"],"award-info":[{"award-number":["R00 MH118134"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oral preexposure prophylaxis (PrEP) effectively reduces HIV incidence when used with sufficient adherence, but does not protect against bacterial sexually transmitted infections (STIs). Several studies have documented high rates of bacterial STIs among individuals initiating and using PrEP. We evaluated the association between PrEP use and the risk of STI among African women accessing family planning clinics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We conducted a prospective cohort study nested within a large pragmatic stepped-wedge cluster randomized trial of PrEP delivery in Kenyan family planning clinics, with participant enrollment from June 18, 2021, to May 18, 2023, and follow-up through February 02, 2024 (ClinicalTrials.gov: NCT04666792). The study population included sexually active HIV\u2013negative women aged \u226515 years at elevated HIV risk per Kenyan PrEP guidelines. Participants were offered standard-of-care oral PrEP with the option to decline and followed quarterly for 12 months with assessments of HIV status, sexual behavior, and PrEP use. Urine samples were batch tested for\n                      <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                      and\n                      <jats:italic>Chlamydia trachomatis<\/jats:italic>\n                      using the GeneXpert CT\/NG real-time polymerase chain reaction nucleic acid amplification test assay. The primary exposure was self-reported PrEP initiation and PrEP use consistency through 6 months, categorized as never used PrEP, inconsistently on PrEP, or consistently on PrEP. Multivariable modified Poisson generalized estimating equation (GEE) models with robust standard errors were used to estimate associations between PrEP use and incident STI; clinic-level intracluster correlation coefficients were negligible. The secondary outcomes were incident HIV infection and sexual behaviors, which included condomless sex at last sex, sex with any new partners in the past 3 months, and multiple sex partners. HIV testing was performed at each scheduled visit, at enrollment, and 1, 3, 6, 9, and 12 months following the Kenya national HIV testing algorithm, using Determine HIV-1\/2 and Fast Response test kits. All models for the primary outcome were adjusted for baseline covariates determined apriori as potential confounders, which included age, STI diagnosis at enrollment, any contraceptive use, number of sexual partners (categorized as any more than one sexual partner), education status, marital status, last partner HIV status, any transactional sex in 3 months pre-enrollment, and clinic site.\n                    <\/jats:p>\n                    <jats:p>\n                      Among 650 women enrolled, 60.0% (389) initiated PrEP at baseline and 14.6% (38\/261) initiated post-enrollment. Median age was 26 years (IQR 23\u201330), 40% (262\/650) were aged \u226424 years, and 67% (436\/648) did not know their primary partner\u2019s HIV status. At baseline, 11% (74\/650) had an STI, including 9.9% (23\/232) of consistent PrEP users, 9.2% (13\/141) of inconsistent users, and 14.0% (38\/277) of women who declined PrEP. During follow-up, 19.1% (114\/597) had at least one STI diagnosis, with similar risk among women who initiated PrEP at baseline compared with those who declined (19.2% [68\/354] versus 18.9% [46\/244]; aRR 1.11, 95% CI 0.76\u20131.61;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.580). Compared with non-PrEP users (12.7% [25\/195]), STI risk was 6.0% (12\/200) among consistent PrEP users (aRR 0.56, 95% CI 0.27\u20131.19;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.130) and 16.5% (17\/103) among inconsistent users (aRR 1.43, 95% CI 0.73\u20132.77;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.290). Chlamydia accounted for 87.7% (100\/114) of STI diagnoses. STI risk was higher among women aged \u226424 years (aRR 1.47, 95% CI 1.04\u20132.07;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029) and those with a baseline STI (aRR 2.96, 95% CI 2.12\u20134.14;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Four HIV infections occurred over 594 person-years (incidence 0.67, 95% CI 0.18\u20131.72 per 100 person-years), including three among women who declined PrEP (incidence 1.25, 95% CI 0.26\u20133.66 per 100 person-years). The main study limitation was oral PrEP use was assessed based on client self-report and not objectively through drug levels testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this prospective cohort study among African women at elevated risk for HIV, 60% initiated PrEP at baseline and 14.6% (38\/261) post-enrollment. PrEP use was not associated with increased risk for STI diagnosis through one year of follow-up. HIV incidence was low overall, consistent with expanded PrEP availability in similar populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004962","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:01:12Z","timestamp":1773086472000},"page":"e1004962","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral preexposure prophylaxis use and the risk of bacterial sexually transmitted infections and HIV among African women: A prospective observational cohort study"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6046-2715","authenticated-orcid":true,"given":"David","family":"Mukasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kinuthia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Meisner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Matemo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torin","family":"Schaafsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3080-6254","authenticated-orcid":true,"given":"Jennifer","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Wandera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-431X","authenticated-orcid":true,"given":"Elvira","family":"Budiawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valarie","family":"Kemuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherotich","family":"Irine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Odhiambo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercy","family":"Bii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Oduor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Achieng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessy","family":"Oyombra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugochinyere Vivian","family":"Ukah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-7468","authenticated-orcid":true,"given":"Kenneth K.","family":"Mugwanya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the FP Plus Project Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"pmed.1004962.ref001","unstructured":"UNAIDS. 2025 global AIDS update \u2013 AIDS, crisis and the power to transform. 2025."},{"key":"pmed.1004962.ref002","unstructured":"UNAIDS. The path that ends AIDS: UNAIDS global AIDS update. 2023."},{"issue":"2","key":"pmed.1004962.ref003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002511","article-title":"Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies","volume":"15","author":"EA Torrone","year":"2018","journal-title":"PLoS Med"},{"issue":"22","key":"pmed.1004962.ref004","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.2019.6390","article-title":"Preexposure prophylaxis for the prevention of HIV infection: US preventive services task force recommendation statement","volume":"321","author":"US Preventive Services Task Force","year":"2019","journal-title":"JAMA"},{"key":"pmed.1004962.ref005","author":"Antiretroviral TS","year":"2015"},{"key":"pmed.1004962.ref006","unstructured":"Control, C.f.D., Prevention, and U.P.H. Service. Preexposure prophylaxis for the prevention of HIV infection in the United States \u2013 2017 Update: a clinical practice guideline. 2018."},{"issue":"5","key":"pmed.1004962.ref007","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jana.2018.06.001","article-title":"Preventing HIV infection in high-risk adolescents using preexposure prophylaxis (PrEP)","volume":"29","author":"CW Blackwell","year":"2018","journal-title":"J Assoc Nurses AIDS Care"},{"issue":"1","key":"pmed.1004962.ref008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0000000000001179","article-title":"An HIV preexposure prophylaxis demonstration project and safety study for young MSM","volume":"74","author":"SG Hosek","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pmed.1004962.ref009","unstructured":"World Health Organization. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection: module 10: testing providers. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection: module 10: testing providers. 2017."},{"key":"pmed.1004962.ref010","unstructured":"AVAC. The future of ARV\u2010based prevention and more. 2024. [cited 2024 July 29]. Avilable from: https:\/\/avac.org\/resource\/infographic\/the-future-of-arv-based-prevention-and-more\/"},{"issue":"11","key":"pmed.1004962.ref011","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(18)30215-7","article-title":"Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study","volume":"5","author":"AE Grulich","year":"2018","journal-title":"Lancet HIV"},{"key":"pmed.1004962.ref012","volume-title":"Scale-up of pre-exposure prophylaxis in San Francisco to impact HIV incidence","author":"R Grant","year":"2015"},{"issue":"151","key":"pmed.1004962.ref013","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"PL Anderson","year":"2012","journal-title":"Sci Transl Med"},{"issue":"11","key":"pmed.1004962.ref014","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(14)70937-5","article-title":"Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial","volume":"14","author":"JM Baeten","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pmed.1004962.ref015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"27","key":"pmed.1004962.ref016","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"RM Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"pmed.1004962.ref017","unstructured":"World Health Organization. Report on global sexually transmitted infection surveillance 2015. 2016."},{"issue":"3","key":"pmed.1004962.ref018","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/sti.78.3.187","article-title":"The feasibility of integrated STI prevalence and behaviour surveys in developing countries","volume":"78","author":"EW MacLachlan","year":"2002","journal-title":"Sex Transm Infect"},{"issue":"11","key":"pmed.1004962.ref019","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2471\/BLT.08.059212","article-title":"Control of sexually transmitted infections and prevention of HIV transmission: mending a fractured paradigm","volume":"87","author":"R Steen","year":"2009","journal-title":"Bull World Health Organ"},{"issue":"14","key":"pmed.1004962.ref020","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1177\/0956462418782810","article-title":"High prevalence of sexually transmitted infections among women screened for a contraceptive intravaginal ring study, Kisumu, Kenya, 2014","volume":"29","author":"VO Oliver","year":"2018","journal-title":"Int J STD AIDS"},{"key":"pmed.1004962.ref021","doi-asserted-by":"crossref","DOI":"10.1097\/01.olq.0000235177.30718.84","article-title":"The costs of treating curable sexually transmitted infections in low- and middle-income countries: a systematic review","volume":"33","author":"F Terris-Prestholt","year":"2006","journal-title":"Sex Transm Dis"},{"key":"pmed.1004962.ref022","volume-title":"Reported STDs in the United States: 2014 national data for chlamydia, gonorrhea, and syphilis","author":"Control, C.f.D. and Prevention","year":"2014"},{"issue":"5","key":"pmed.1004962.ref023","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/QAD.0000000000001386","article-title":"Serious concerns regarding a meta-analysis of preexposure prophylaxis use and STI acquisition","volume":"31","author":"NT Harawa","year":"2017","journal-title":"AIDS"},{"issue":"4","key":"pmed.1004962.ref024","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/QAI.0000000000001604","article-title":"Pre-exposure prophylaxis (PrEP) use and condomless anal sex: evidence of risk compensation in a cohort of young men who have sex with men","volume":"77","author":"ME Newcomb","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"pmed.1004962.ref025","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/QAI.0b013e3181e19a54","article-title":"Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men","volume":"54","author":"SA Golub","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"pmed.1004962.ref026","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s43058-021-00228-4","article-title":"Integrating PrEP delivery in public health family planning clinics: a protocol for a pragmatic stepped wedge cluster randomized trial in Kenya","volume":"2","author":"KK Mugwanya","year":"2021","journal-title":"Implement Sci Commun"},{"key":"pmed.1004962.ref027","volume-title":"Guidelines on use of antiretroviral drugs for treating and preventing HIV infection in Kenya","author":"NA, M.o.H, and SCP","year":"2016"},{"issue":"11","key":"pmed.1004962.ref028","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(14)70937-5","article-title":"Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial","volume":"14","author":"JM Baeten","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pmed.1004962.ref029","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","article-title":"HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention","volume":"66","author":"D Donnell","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9731","key":"pmed.1004962.ref030","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/S0140-6736(10)60705-2","article-title":"Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis","volume":"375","author":"D Donnell","year":"2010","journal-title":"Lancet"},{"issue":"18","key":"pmed.1004962.ref031","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1097\/QAD.0000000000000493","article-title":"Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception","volume":"28","author":"R Heffron","year":"2014","journal-title":"AIDS"},{"issue":"2","key":"pmed.1004962.ref032","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/apc.2015.0259","article-title":"I knew I would be safer. Experiences of Kenyan HIV serodiscordant couples soon after pre-exposure prophylaxis (PrEP) initiation","volume":"30","author":"K Ngure","year":"2016","journal-title":"Aids Patient Care and Stds"},{"issue":"5","key":"pmed.1004962.ref033","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"pmed.1004962.ref034","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/infdis\/jiw125","article-title":"Low risk of proximal tubular dysfunction associated with emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis in men and women","volume":"214","author":"K Mugwanya","year":"2016","journal-title":"J Infect Dis"},{"issue":"4","key":"pmed.1004962.ref035","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/QAI.0000000000000868","article-title":"Reversibility of glomerular renal function decline in HIV-uninfected men and women discontinuing emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis","volume":"71","author":"KK Mugwanya","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"pmed.1004962.ref036","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamainternmed.2014.6786","article-title":"Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial","volume":"175","author":"KK Mugwanya","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"9","key":"pmed.1004962.ref037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002132","article-title":"Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption","volume":"13","author":"KK Mugwanya","year":"2016","journal-title":"PLoS Med"},{"issue":"8","key":"pmed.1004962.ref038","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/aje\/kwr183","article-title":"Performance of the modified Poisson regression approach for estimating relative risks from clustered prospective data","volume":"174","author":"LN Yelland","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"11","key":"pmed.1004962.ref039","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamapediatrics.2017.2007","article-title":"Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States","volume":"171","author":"SG Hosek","year":"2017","journal-title":"JAMA Pediatr"},{"key":"pmed.1004962.ref040","unstructured":"Siegler AJ, et al. Distribution of active PrEP prescriptions and the PrEP-to-need ratio, US, Q2 2017. Boston; 2018."},{"key":"pmed.1004962.ref041","volume-title":"The path that ends AIDS","author":"Update, U.G.A","year":"2023"},{"issue":"25","key":"pmed.1004962.ref042","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2304007","article-title":"Doxycycline prophylaxis to prevent sexually transmitted infections in women","volume":"389","author":"J Stewart","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"pmed.1004962.ref043","article-title":"Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis","volume":"2","author":"JJ Ong","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"pmed.1004962.ref044","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/sextrans-2021-055381","article-title":"Pre-exposure prophylaxis and bacterial sexually transmitted infections (STIs) among gay and bisexual men","volume":"99","author":"TA Hart","year":"2023","journal-title":"Sex Transm Infect"},{"issue":"3","key":"pmed.1004962.ref045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/QAI.0000000000002134","article-title":"PrEP use among female sex workers: no evidence for risk compensation","volume":"82","author":"K Gigu\u00e8re","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"pmed.1004962.ref046","article-title":"Limited risk compensation among women who inject drugs: results from the project sexual health equity preexposure prophylaxis demonstration study in Philadelphia","volume":"49","author":"NK Tran","year":"2022","journal-title":"Sex Transm Dis"},{"issue":"4","key":"pmed.1004962.ref047","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/QAD.0000000000001718","article-title":"Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV","volume":"32","author":"V-K Nguyen","year":"2018","journal-title":"AIDS"},{"issue":"12","key":"pmed.1004962.ref048","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/13691058.2017.1310927","article-title":"Risk, safety and sex among male PrEP users: time for a new understanding","volume":"19","author":"K Koester","year":"2017","journal-title":"Cult Health Sex"},{"issue":"12","key":"pmed.1004962.ref049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081997","article-title":"No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis","volume":"8","author":"JL Marcus","year":"2013","journal-title":"PLoS One"},{"key":"pmed.1004962.ref050","unstructured":"United Nations. The millennium development goals report. 2010 [cited 2019 Sep 03]. Available from: http:\/\/mdgs.un.org\/unsd\/mdg\/Resources\/Static\/Products\/Progress2010\/MDG_Report_2010_En.pdf"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004962","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:45:27Z","timestamp":1773942327000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004962"}},"subtitle":[],"editor":[{"given":"Sydney","family":"Rosen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004962","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}